BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human antibodies, such as TB-402, TB-403, BI-204 and BI-505, as well as licenses. BioInvent is active in the co-development of intellectual property through strategic product alliances with ThromboGenics Ltd and Roche Group. It has has entered into several product partnerships with Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. As of December 31, 2011, the Company had one wholly owned subsidiary BioInvent Finans AB, engaged in the administration of warrants issued by the Company. As of December 31, 2011, the Companyâ€™s largest shareholder was JP Morgan Bank. In May 2014, the Company sold back all its rights to product candidate ADC-1013 to its former partner Alligator Bioscience AB.